Brainstorm Cell Therapeutics Inc. Q2 2025 Earnings Recap

Brainstorm Cell Therapeutics reported a net loss of $2.9 million for Q2 2025 while making significant progress towards launching its crucial Phase IIIb clinical trial for NurOwn, following FDA clearance.

Key Takeaways

• The Phase IIIb trial, ENDURANCE, received FDA clearance, allowing patient enrollment to begin.
• Partnership established with Minaris Advanced Therapies to enhance U.S.-based manufacturing capabilities for clinical trial supplies.
• New citizens petition submitted to the FDA by ALS advocates requesting a review of NurOwn data, potentially impacting regulatory pathways.
• Net loss of $2.9 million for Q2 2025, compared to a loss of $2.5 million in the same quarter last year.
• Company's stock has transitioned from NASDAQ to OTCQB due to noncompliance with minimum shareholder equity requirements, but business operations remain unaffected.